New combo therapy aims to fight hard-to-treat lymphoma

NCT ID NCT05996185

Recruiting now Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests adding the drug mogamulizumab to standard chemotherapy for people with aggressive T-cell lymphoma, a type of blood cancer. About 22 adults with newly diagnosed or returning lymphoma will receive the combination treatment. The goal is to see if more patients achieve complete remission and to monitor side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma primary cutaneous T-cell non-Hodgkin lymphoma Recurrence T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10029, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Yale Cancer Center, Clinical Trials Office
RECRUITING

New Haven, Connecticut, 06510, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact